Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | NPY4R | P50391 | 3/20 | 0.31 |
| ▸ | NPY1R | P25929 | 2/20 | 0.31 |
| ▸ | NPY2R | P49146 | 2/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.31 |
| ▸ | OTC | P00480 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14367895 | 0.84 | MEN1 (0.44) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL20764127 | 0.82 | MEN1 (0.42) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL20969045 | 0.82 | MEN1 (0.42) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL463757 | 0.82 | MEN1 (0.42) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL13865707 | 0.82 | MEN1 (0.42) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL20406274 | 0.81 | MEN1 (0.45) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL17985760 | 0.80 | MEN1 (0.41) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL20822004 | 0.80 | MEN1 (0.41) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL4883177 | 0.80 | MEN1 (0.41) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL6545309 | 0.80 | MEN1 (0.41) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081363-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2024-04-18 | — | — | WO | disclosed |
| EP-1615946-B1 | PROTEOLYTIC AND COVALENT ANTIBODIES | PAUL SUDHIR (US) | 2020-05-06 | — | — | EP | disclosed |
| US-9006388-B2 | Covalent attachment of ligands to nucleophilic proteins guided by non-covalent | Paul, Sudhir (US) | 2015-04-14 | — | — | US | disclosed |
| US-8980646-B2 | Proteolytic and covalent antibodies | PAUL, SUDHIR (US) | 2015-03-17 | — | — | US | disclosed |
| US-20070179083-A1 | Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding | COVALENT BIOSCIENCE INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-20070105092-A1 | Proteolytic and covalent antibodies | COVALENT BIOSCIENCE INCORPORATED | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179083-A1 | Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding | FABP1, FPR1, ADGRF1 | MEN1 4768/4885CYP1A2 2713/4885KMT2A 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.